Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous mezagitamab in chronic primary immune thrombocytopenia
jRCT2031240667Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) and chronic primary immune thrombocytopenia (ITP) comparing Mezagitamab with Placebo (2 arms). Primary endpoint: Percentage of participants with durable platelet response. Started Feb 2025; status: recruiting.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenia (ITP)chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2031240667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240667.